secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001193125-22-220557
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme proposes $500M convertible notes due 2028, plans $200M share repurchase and debt repayment
--------------------------------------------------------------------------------

- $500M aggregate principal of convertible senior notes due 2028; initial purchasers have option for additional $75M.
- Proceeds uses: up to $200M share repurchases (increase of $100M vs prior 2022 plan), exchange of existing 1.25% convertibles, and repayment of $250M term loan due 2026.
- Capped call transactions will be entered to reduce potential dilution upon conversion of the notes.
- Interest rate and conversion rate determined at pricing; conversions settled in cash plus stock if applicable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000119312522220557/0001193125-22-220557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000119312522220557/d295619d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-220557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer